Results
|
1.
|
|
|
2.
|
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. MedStar authors:
Year: 2016
Citation: - Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Anderson SJ, Cecchini RS, Costantino JP, Geyer CE Jr, Jeong JH, Lembersky BC, Paterson AH, Rastogi P, Romond EH, Swain SM, Tang G, Wolmark N
|
|
3.
|
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. MedStar authors:
Citation: - Lancet Oncology. 14(9):901-8, 2013 Aug.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
All authors: - Blay JY, Chawla S, Choy E, Ferrari S, Grimer R, Henshaw R, Jacobs I, Kroep J, Qian Y, Reichardt P, Rutkowski P, Schuetze S, Seeger L, Skubitz K, Staddon A, Thomas D
|
|
4.
|
|
|
5.
|
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(12):1719-1729, 2019 12.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Blay JY, Chawla S, Choy E, Dai T, Gelderblom H, Grimer RJ, Henshaw R, Jandial D, Le Cesne A, Palmerini E, Reichardt P, Rutkowski P, Schuetze SM, Seeger L, Skubitz K
|
|
6.
|
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. MedStar authors:
Year: 2016
Citation: - Annals of Surgical Oncology. 24(7):1853-1860, 2017 Jul
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Kidwell KM, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA, Zoon CK
|
|
7.
|
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. MedStar authors:
Year: 2018
Citation: - World Journal of Surgical Oncology. 16(1):191, 2018 Sep 19.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Bach BA, Braun A, Chawla S, Choy E, Engellau J, Feng A, Gelderblom H, Grimer R, Henshaw R, Jacobs I, O'Neal M, Reichardt P, Roberts ZJ, Seeger L
|
|
8.
|
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(11):1493-1501, 2017 Nov
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Baker LH, Bolejack V, Burgess M, Butterfield LH, Crowley J, D'Angelo S, Davis LE, Hu J, Lazar AJ, Maki RG, Movva S, Okuno SH, Patel S, Priebat DA, Reed DR, Reinke D, Riedel RF, Rodriguez-Canales J, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wistuba II
|
|
9.
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM
|
|
10.
|
Neoadjuvant Chemotherapy and Nipple-Sparing Mastectomy: Timing and Postoperative Complications. MedStar authors:
- Dervishaj, Ornela A
- Tung, Shawndeep S
Year: 2019
Citation: - Annals of Surgical Oncology. 26(9):2768-2772, 2019 Sep.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Bartholomew AJ, Caragacianu DL, Dervishaj OA, Kerivan LT, Sosin M, Tousimis EA, Tung SS, Willey SC
|
|
11.
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. MedStar authors:
Year: 2013
Citation: - Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Atkins JN, Azar CA, Biggs DD, Brufsky AM, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE Jr, Levine EA, Mamounas EP, Northfelt DW, Paik S, Polikoff JA, Provencher L, Rastogi P, Robidoux A, Swain SM, Tang G, Wolmark N, Zapas JL
|
|
12.
|
|
|
13.
|
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(16):4233-4241, 2020 08 15.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Bandos H, Brauer HA, Geyer CE Jr, Goerlitz DS, Harris BT, Lucas PC, Mamounas EP, Rastogi P, Ren Y, Robidoux A, Swain SM, Tang G, Wolmark N
|
|
14.
|
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. MedStar authors:
Year: 2017
Citation:
- JAMA Oncology. , 2017 Feb 09
- JAMA Oncology. 3(7):944-952, 2017 Jul 01
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baker LH, Benjamin RS, Blackstein ME, Blanke CD, Borden EC, Corless CL, Crowley JJ, Demetri GD, Fletcher JA, Heinrich M, Maki RG, Owzar K, Priebat DA, Rankin C, Ryan CW, Tap WD, von Mehren M
|
|
15.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|